awmsg logo

paclitaxel albumin-bound nanoparticles (Abraxane®)

Reference No. 232

Publication date:

Appraisal information

paclitaxel albumin-bound nanoparticles (Abraxane®) powder for suspension for infusion

Company: Abraxis BioScience Ltd
BNF category: Malignant disease and immunosupression
NMG meeting date: 17/03/2010
AWMSG meeting date: 28/04/2010
Submission Type: Full Submission
Status: Recommended
Advice No: 0410
Ratification by Welsh Government: 28/05/2010

Current Progress

Ratification by
Welsh Government

AWMSG advice

Paclitaxel albumin (Abraxane®) monotherapy is recommended as an option for use within NHS Wales for the treatment of metastatic breast cancer in patients who have failed first-line treatment for metastatic disease and for who standard, anthracycline containing therapy is not indicated. AWMSG is of the opinion that paclitaxel albumin (Abraxane®) is not suitable for shared care within NHS Wales. Clinicians should follow the National Institute for Health and Clinical Excellence (NICE) Guidelines CG81 in the consideration of treatment options for metastatic breast cancer. The Summary of Product Characteristics specifically states that this drug should be used as monotherapy. In order to limit potential errors, paclitaxel albumin (Abraxane®) should be prescribed by brand as Abraxane®.
Final Appraisal Recommendation (FAR)